Takanami Iwao
Department of Surgery, Teikyo University School of Medicine, 11-1 Kaga 2-Chome, Tokyo 173-8605, Japan.
Oncol Rep. 2006 Feb;15(2):437-42.
The monoclonal antibody D2-40 is a new selective marker for lymphatic endothelium. The lymphatic microvessel density (LMVD) using D2-40 has not yet been evaluated in non-small cell lung cancer (NSCLC). The aim of this study was to evaluate LMVD using D2-40 in NSCLC. We investigated LMVD in 77 patients with NSCLC who underwent curative tumor resection. We also determined the relation between LMVD and clinicopathologic factors, VEGF-C and Ang-2 and microvessel density (MVD) using factor VIII-related antigen. The median number of D2-40-positive vessels in the highest LMVD was 25 (range, 5-71). LMVD was significantly associated with tumor status, lymph node metastasis, stage, lymphatic invasion, VEGF-C protein and MVD (p=0.0149 for tumor status; p<0.0001 for nodal status; p<0.0001 for stage; p=0.0153 for lymphatic invasion; p=0.0030 for VEGF-C, and p=0.0029 for MVD). Furthermore, LMVD using D2-40 expression was shown to be an independent predictor of lymph node metastasis by multivariate analysis (p=0.0070). These data indicate that a high LMVD by D2-40 may be an indicator of lymph node metastasis in NSCLC.
单克隆抗体D2-40是一种新型的淋巴管内皮细胞选择性标志物。在非小细胞肺癌(NSCLC)中,尚未评估使用D2-40检测的淋巴管微血管密度(LMVD)。本研究旨在评估在NSCLC中使用D2-40检测的LMVD。我们调查了77例行根治性肿瘤切除术的NSCLC患者的LMVD。我们还确定了LMVD与临床病理因素、VEGF-C和Ang-2以及使用VIII因子相关抗原检测的微血管密度(MVD)之间的关系。LMVD最高组中D2-40阳性血管的中位数为25(范围5-71)。LMVD与肿瘤状态、淋巴结转移、分期、淋巴管浸润、VEGF-C蛋白和MVD显著相关(肿瘤状态p=0.0149;淋巴结状态p<0.0001;分期p<0.0001;淋巴管浸润p=0.0153;VEGF-C p=0.0030,MVD p=0.0029)。此外,多因素分析显示,使用D2-40表达检测的LMVD是淋巴结转移的独立预测指标(p=0.0070)。这些数据表明,D2-40检测到的高LMVD可能是NSCLC患者淋巴结转移的一个指标。